MA55015A - Formulations pharmaceutiques - Google Patents

Formulations pharmaceutiques

Info

Publication number
MA55015A
MA55015A MA055015A MA55015A MA55015A MA 55015 A MA55015 A MA 55015A MA 055015 A MA055015 A MA 055015A MA 55015 A MA55015 A MA 55015A MA 55015 A MA55015 A MA 55015A
Authority
MA
Morocco
Prior art keywords
pharmaceutical formulations
formulations
pharmaceutical
Prior art date
Application number
MA055015A
Other languages
English (en)
Inventor
René Holm
Kristof Leonard Kimpe
Audrey Antoinette Renée Lathuile
Thomas Eddy R Neefs
Hana Prokopcová
Sanket Manoj Shah
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA55015A publication Critical patent/MA55015A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA055015A 2019-02-22 2020-02-20 Formulations pharmaceutiques MA55015A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2019075844 2019-02-22

Publications (1)

Publication Number Publication Date
MA55015A true MA55015A (fr) 2021-12-29

Family

ID=69650609

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055015A MA55015A (fr) 2019-02-22 2020-02-20 Formulations pharmaceutiques

Country Status (21)

Country Link
US (1) US20220175760A1 (fr)
EP (1) EP3927324A1 (fr)
JP (1) JP2022523371A (fr)
KR (1) KR20210132099A (fr)
CN (1) CN113473971B (fr)
AU (1) AU2020225342A1 (fr)
BR (1) BR112021016411A2 (fr)
CA (1) CA3129356A1 (fr)
CR (1) CR20210480A (fr)
EA (1) EA202192322A1 (fr)
EC (1) ECSP21067816A (fr)
IL (1) IL285674A (fr)
JO (1) JOP20210230A1 (fr)
MA (1) MA55015A (fr)
MX (1) MX2021010144A (fr)
PE (1) PE20212323A1 (fr)
PH (1) PH12021552020A1 (fr)
SG (1) SG11202109102PA (fr)
TW (1) TW202045159A (fr)
UY (1) UY38593A (fr)
WO (1) WO2020169738A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為malt1抑制劑之吡唑衍生物
US12404260B2 (en) 2019-04-11 2025-09-02 Janssen Pharmaceutica Nv Pyridine rings containing derivatives as MALT1 inhibitors
EP4199911A1 (fr) * 2020-08-21 2023-06-28 JANSSEN Pharmaceutica NV Formulations pharmaceutiques comprenant un inhibiteur de malt1 et un mélange de polyéthylèneglycol et d'un acide gras
JP2023539729A (ja) 2020-08-21 2023-09-19 ヤンセン ファーマシューティカ エヌ.ベー. Malt1阻害剤の非晶質形態及びその製剤
KR20230154227A (ko) * 2021-03-03 2023-11-07 얀센 파마슈티카 엔브이 치료적 유효 용량의 malt1 억제제 jnj-67856633(1-(1-옥소-1,2-다이하이드로아이소퀴놀린-5-일)-5-(트라이플루오로메틸)-n-(2-(트라이플루오로메틸)피리딘-4-일)-1h-피라졸-4-카르복스아미드)을 사용하는 병태의 치료 방법
JP2025501056A (ja) * 2021-12-30 2025-01-17 シャンハイ ハンソー バイオメディカル カンパニー リミテッド 三環系誘導体阻害剤、その製造方法と応用
AU2024357109A1 (en) 2023-10-06 2026-03-12 Ionctura Sa Combination of roginolisib with a malt1-gls inhibitor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2006037348A1 (fr) * 2004-10-01 2006-04-13 Lifecycle Pharma A/S Compositions pharmaceutiques contenant du fenofibrate et une statine
EP2395838B1 (fr) * 2009-02-11 2018-07-25 Cadila Pharmaceuticals Ltd. Composition pharmaceutique stable pour l'athérosclérose
TW201040181A (en) * 2009-04-08 2010-11-16 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
US8252821B2 (en) * 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
MA37711A1 (fr) * 2012-06-04 2017-05-31 Pharmacyclics Inc Formes cristallines d'un inhibiteur de tyrosine kinase de bruton
IL315294A (en) * 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of proton tyrosine kinase inhibitor
CN107296807B (zh) * 2016-04-15 2020-03-20 中国科学院上海生命科学研究院 Malt1靶向抑制物在制备malt1依赖性肿瘤治疗药物中的应用
TWI795381B (zh) * 2016-12-21 2023-03-11 比利時商健生藥品公司 作為malt1抑制劑之吡唑衍生物

Also Published As

Publication number Publication date
SG11202109102PA (en) 2021-09-29
CN113473971A (zh) 2021-10-01
MX2021010144A (es) 2021-09-14
EP3927324A1 (fr) 2021-12-29
CN113473971B (zh) 2024-07-02
EA202192322A1 (ru) 2021-12-03
AU2020225342A1 (en) 2021-08-19
KR20210132099A (ko) 2021-11-03
IL285674A (en) 2021-10-31
CR20210480A (es) 2021-11-10
JP2022523371A (ja) 2022-04-22
PE20212323A1 (es) 2021-12-14
ECSP21067816A (es) 2021-12-30
PH12021552020A1 (en) 2022-09-12
US20220175760A1 (en) 2022-06-09
UY38593A (es) 2020-08-31
WO2020169738A1 (fr) 2020-08-27
CA3129356A1 (fr) 2020-08-27
JOP20210230A1 (ar) 2023-01-30
BR112021016411A2 (pt) 2021-10-13
TW202045159A (zh) 2020-12-16

Similar Documents

Publication Publication Date Title
EP4045480A4 (fr) Formulations pharmaceutiques
EP3817722A4 (fr) Compositions pharmaceutiques comprenant du méloxicam
MA52421A (fr) Composés pharmaceutiques
MA50541A (fr) Formulations pharmaceutiques
EP3541385A4 (fr) Formulations pharmaceutiques
IL285674A (en) Pharmaceutical formulations
MA42303A (fr) Formulations pharmaceutiques
SI3927315T1 (sl) Okusne formulacije
HUE057877T2 (hu) Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására
DK4233850T3 (da) Kapselformuleringer
EP3914234A4 (fr) Compositions pharmaceutiques
EP3897593A4 (fr) Formulations de cannabinoïdes et compositions pharmaceutiques
EP3746080A4 (fr) Formulations pharmaceutiques
MA49837A (fr) Compositions pharmaceutiques
EP4015001A4 (fr) Composition pharmaceutique orale
DK3908321T3 (da) Farmaceutisk sammensætning
EP3337463A4 (fr) Formulations pharmaceutiques
EP3638211A4 (fr) Compositions pharmaceutiques à libération prolongée retardée
EP3873437A4 (fr) Formulations pharmaceutiques aqueuses
DK4027973T3 (da) Formuleringer til lægemiddeladministration
CR20220587A (es) Formulaciones farmacéuticas
PL3787596T3 (pl) Ulepszone formulacje farmaceutyczne
DK3911298T3 (da) Formuleringer
PT3949952T (pt) Composição farmacêutica
EP3651800A4 (fr) Formulations pharmaceutiques hydrocompressées